In addition, our nuclear proteome profiling also uncovered nuclear changes in metabolic enzymes that link organelle metabolic state to the epigenome and in several therapeutic targets already used in the context of NASH, such as PPARγ, farnesoid X receptor (FXR), thyroid hormone receptor (THR), and pregnane X receptor (PXR) (Trauner & Fuchs, 2022; Umemura et al, 2022). This evidence concerns the gene NR1I2 and metabolic dysfunction-associated steatohepatitis.